Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 34Lymphoma, Non-Hodgkin 30Leukemia, Myeloid, Acute 25Hodgkin Disease 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Myelodysplastic Syndromes 11Lymphoma 10Leukemia, Lymphocytic, Chronic, B-Cell 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia 6Neoplasms, Plasma Cell 5Recurrence 3Pancreatic Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Hematologic Neoplasms 3Gliosarcoma 3Glioblastoma 3Warts 2Sezary Syndrome 2Neutropenia 2Myeloproliferative Disorders 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Hairy Cell 2Infections 2Immunologic Deficiency Syndromes 2

Interventions

Cytarabine 14fludarabine 13venetoclax 11Imatinib Mesylate 9Cyclophosphamide 8Azacitidine 8fludarabine phosphate 7Busulfan 7Whole-Body Irradiation 6Tacrolimus 6Mycophenolic Acid 6thymoglobulin 4ponatinib 4nilotinib 4Sirolimus 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4asciminib 3aldesleukin 3Melphalan 3Interleukin-2 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Decitabine 3Antilymphocyte Serum 3zosuquidar trihydrochloride 2gilteritinib 2enasidenib 2blinatumomab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Leukemia, Myeloid × plerixafor × Clear all
NCT00943943 2017-03-29

Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

M.D. Anderson Cancer Center

Phase 1 Completed
33 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡